DM
ACRS icon

Deerfield Management’s Aclaris Therapeutics ACRS Stock Holding History

Deerfield Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,983,025
Closed -$8.72M – 96
2019
Q2 		$8.72M Sell
3,983,025
-1,910,391
-32% -$10.4M 0.31% 75
2019
Q1 		$35.3M Hold
5,893,416
– – 1.35% 24
2018
Q4 		$43.6M Buy
5,893,416
+2,800,000
+91% +$28.9M 1.74% 17
2018
Q3 		$44.9M Buy
3,093,416
+347,711
+13% +$5.96M 1.61% 22
2018
Q2 		$54.8M Hold
2,745,705
– – 1.93% 11
2018
Q1 		$48.1M Buy
2,745,705
+512,289
+23% +$10.9M 1.67% 14
2017
Q4 		$55.1M Buy
2,233,416
+655,489
+42% +$16M 2.17% 11
2017
Q3 		$40.7M Buy
1,577,927
+1,202,927
+321% +$32.2M 1.83% 15
2017
Q2 		$10.2M Hold
375,000
– – 0.54% 54
2017
Q1 		$11.2M Hold
375,000
– – 0.43% 61
2016
Q4 		$10.2M Buy
375,000
+259,000
+223% +$6.6M 0.42% 61
2016
Q3 		$2.97M Buy
+116,000
New +$2.46M 0.14% 72

Other funds holding ACRS

Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management's ACRS Position: Q3 2019 in Review

Deerfield Management sold out of Aclaris Therapeutics (ACRS) in Q3 2019, closing a stake of 3,983,025 shares — an estimated $8.72M sold.

Deerfield Management first reported a position in ACRS in Q3 2016 and held it in 12 quarters. The position peaked at $55.1M in Q4 2017. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2019.

  • Deerfield Management reported no remaining Aclaris Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Deerfield Management sold 3,983,025 Aclaris Therapeutics shares in Q3 2019, an estimated $8.72M.
  • Deerfield Management first reported a position in Aclaris Therapeutics in Q3 2016 and held it in 12 quarters.
  • Deerfield Management's Aclaris Therapeutics position peaked at $55.1M in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2019.

Based on Deerfield Management's 13F filing for Q3 2019, filed 14 Nov 2019.